This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sweeney, M. O. Articles by Dec, G. W. Search for Related Content PubMed PubMed Citation Articles by Sweeney, M. O. Articles by Dec, G. W. Pubmed/NCBI databases Medline Plus Health Information Cardiac Arrest Heart Failure Heart Transplantation Pacemakers and Implantable Defibrillators

(Circulation. 1995;92:3273-3281.)
© 1995 American Heart Association, Inc.

Articles

Influence of the Implantable Cardioverter/Defibrillator on Sudden Death and Total Mortality in Patients Evaluated for Cardiac Transplantation

Michael O. Sweeney, MD; Jeremy N. Ruskin, MD; Hasan Garan, MD; Brian A. McGovern, MD; Mary L. Guy, RN; David F. Torchiana, MD; Gus J. Vlahakes, MD; John B. Newell, BA; Marc J. Semigran, MD; G. William Dec, MD

From the Cardiac Arrhythmia Service (M.O.S., J.N.R., H.G., B.A.M., M.L.G.), Cardiac Surgical Service (D.F.T., G.J.V.), Cardiac Computer Center (J.B.N.), and Heart Failure/Transplantation Service (M.J.S., G.W.D.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Dr G.W. Dec, Heart Failure/Transplantation Service, Massachusetts General Hospital, Boston, MA 02114.

Background Implantable cardioverter/defibrillators (ICDs) may reduce sudden tachyarrhythmic death in patients with severe left ventricular dysfunction. It is uncertain whether this improves survival, particularly in patients awaiting cardiac transplantation.

Methods and Results The effect of treatment for spontaneous ventricular arrhythmias (ICD [n=59], antiarrhythmic drugs [n=53], or no antiarrhythmic treatment [n=179]) on total mortality and mode of cardiac death was analyzed in 291 consecutive patients evaluated for cardiac transplantation between January 1986 and January 1995. There were 109 deaths (37.4%) (63 [21.6%] sudden, 40 [13.7%] nonsudden, and 6 [2.1%] noncardiac) during mean follow-up of 15 months (range, 1 to 118 months). Baseline clinical variables, medical therapies for heart failure, and actuarial rates of transplantation were similar between treatment groups. Kaplan-Meier sudden death rates were lowest in the ICD group, intermediate in the no antiarrhythmic treatment group, and highest in the drug treatment group throughout follow-up (12-month sudden death rates, 9.2%, 16.0%, and 34.7%, respectively; P=.004). Total mortality and nonsudden death rates did not differ. Cox proportional-hazards model revealed that antiarrhythmic drug treatment was associated with sudden death (relative risk, 2.1; 95% CI, 1.04 to 3.39; P=.04) and ICD was associated with nonsudden death (relative risk, 2.26; 95% CI, 1.12 to 4.62; P=.02).

Conclusions Sudden death rates were lowest in patients treated with ICDs compared with drug treatment or no antiarrhythmic treatment. However, although ICDs reduced sudden death in selected high-risk patients with severe left ventricular dysfunction, the effect on long-term survival was limited, principally by high nonsudden death rates.

Key Words: death, sudden • heart failure • transplantation

This article has been cited by other articles:

				D. A. Cesario and G. W. Dec Implantable Cardioverter- Defibrillator Therapy in Clinical Practice J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1507 - 1517. [Abstract] [Full Text] [PDF]

				W. G. Stevenson and L. M. Epstein Predicting Sudden Death Risk for Heart Failure Patients in the Implantable Cardioverter-Defibrillator Age Circulation, February 4, 2003; 107(4): 514 - 516. [Full Text] [PDF]

				Committee Members, G. Gregoratos, J. Abrams, A. E. Epstein, R. A. Freedman, D. L. Hayes, M. A. Hlatky, R. E. Kerber, G. V. Naccarelli, M. H. Schoenfeld, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1703 - 1719. [Full Text] [PDF]

				G. Gregoratos, J. Abrams, A. E. Epstein, R. A. Freedman, D. L. Hayes, M. A. Hlatky, R. E. Kerber, G. V. Naccarelli, M. H. Schoenfeld, M. J. Silka, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) Circulation, October 15, 2002; 106(16): 2145 - 2161. [Full Text] [PDF]

				F Duru, R Candinas, M Lachat, M Rahn, G Noll, T.F Luscher, and M Turina Electrical and mechanical support in advanced heart failure. Rationale and feasibility of a combined management strategy Eur. Heart J., July 1, 2002; 23(13): 1005 - 1010. [Full Text] [PDF]

				J Parkes, J Bryant, and R Milne Implantable cardioverter-defibrillators in arrhythmias: a rapid and systematic review of effectiveness Heart, May 1, 2002; 87(5): 438 - 442. [Abstract] [Full Text] [PDF]

				L. B. Mitchell, E. A. Pineda, J. L. Titus, P. M. Bartosch, and D. G. Benditt Sudden death in patients with implantable cardioverter defibrillators: The importance of post-shock electromechanical dissociation J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1323 - 1328. [Abstract] [Full Text] [PDF]

				C Stellbrink, A.-M Sinha, B Diem, A Auricchio, S Boccanelli, J Brugada, H Klein, J Morgan, L Padeletti, E Aliot, et al. Implantable card ioverter-defibrillators with or without cardiac resynchronization therapy -- multiple therapy in a single device: a review with special reference to the PACIVIAN study Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D88 - D94. [Abstract] [PDF]

				S. E. Sandner, G. Wieselthaler, A. Zuckermann, S. Taghavi, H. Schmidinger, R. Pacher, M. Ploner, G. Laufer, E. Wolner, and M. Grimm Survival Benefit of the Implantable Cardioverter-Defibrillator in Patients on the Waiting List for Cardiac Transplantation Circulation, September 18, 2001; 104(90001): I-171 - 176. [Abstract] [Full Text] [PDF]

				J P Bourke, A Loaiza, G Parry, C Hilton, S Furniss, J Dark, and J Forty Role of orthotopic heart transplantation in the management of patients with recurrent ventricular tachyarrhythmias following myocardial infarction Heart, November 1, 1998; 80(5): 473 - 478. [Abstract] [Full Text]

				D. Bocker, D. Bansch, A. Heinecke, M. Weber, J. Brunn, D. Hammel, M. Borggrefe, G. Breithardt, and M. Block Potential Benefit From Implantable Cardioverter-Defibrillator Therapy in Patients With and Without Heart Failure Circulation, October 20, 1998; 98(16): 1636 - 1643. [Abstract] [Full Text] [PDF]

				E. M. Grubman, B. B. Pavri, T. Shipman, N. Britton, and D. Z. Kocovic Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1056 - 1062. [Abstract] [Full Text] [PDF]

				L. F. P. Moreira, N. A. G. Stolf, E. A. Bocchi, F. Bacal, M. C. P. Giorgi, J. R. Parga, and A. D. Jatene Partial left ventriculectomy with mitral valve preservation in the treatment of patients with dilated cardiomyopathy J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 800 - 807. [Abstract] [Full Text] [PDF]